Tim Smith

This systematic review and meta-analysis of available randomized controlled trials compared biologics for psoriasis, such as ixekizumab, secukinumab, and ustekinumab.

These post hoc findings suggest psychosocial burden may improve following hair regrowth with ritlecitinib.

In this analysis, investigators validated the Automatic Psoriasis Area and Severity Index (APASI), an AI-driven system for psoriasis severity assessment.

This analysis highlights patients with alopecia areata who did not respond to 1 or more JAK inhibitors but saw regrowth after switching to a different JAKi.

In this analysis, investigators highlight the impact of the route of MTX administration on drug survival among patients with psoriasis.

These data highlight secukinumab’s potential as a treatment to provide enhanced psychological outcomes among those with psoriasis.

These new, phase 2 findings on the use of topical bimiralisib suggest positive results among patients with actinic keratosis.

This review explores the safety of oral JAK inhibitors in inflammatory skin conditions, with 43 real-world studies being highlighted.

This study highlighted tildrakizumab’s use in daily practice within a heterogeneous cohort of patients with psoriasis commonly affected by comorbid conditions.

This analysis assesses the positive predictive value of the ICD-10 code for vitiligo commonly used in electronic medical record-based research.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from EADV.

This review of the month of September highlights some of the most significant dermatology headlines.

This review of Q3 developments in the dermatology space highlight a number of significant news stories from 2025.

These phase 3 data, released by MoonLake Immunotherapeutics, highlight week 16 results for patients with hidradenitis suppurativa using sonelokimab.

These data from the ECZTRA 3 and ECZTEND trials highlight tralokinumab’s impact on patients with atopic dermatitis long-term.

These late-breaking data at EADV highlight the impacts of ATI-2138, an oral small-molecule ITK/JAK3 inhibitor, on atopic dermatitis.

In this analysis, the long-term cardiovascular safety of upadacitinib treatment for atopic dermatitis was highlighted.

These new data, presented at EADV, highlight remibrutinib’s impact on specific IgG autoantibody levels in individuals with chronic spontaneous urticaria (CSU).

This approval by the FDA of ruxolitinib cream for children aged 2-11 years atopic dermatitis follows recent positive clinical trial findings on the treatment.

This analysis highlights the safety and efficacy of JAK3/TEC inhibition in cicatricial alopecias, presented at EADV.

These late-breaking data at EADV highlight predictive factors for early super response to treatment with bimekizumab for psoriasis.

These HS-OBTAIN phase 2a trial data highlight the impacts of treatment with brivekimig on patients naïve to biologics with moderate-to-severe HS.

This study highlights improvements with izokibep for HS, sustained or improved across disease measures through to Week 16.

These 24-week, interim data from the phase STOP-HS study highlight the impacts of povorcitinib on patients with hidradenitis suppurativa (HS).

Patients with atopic dermatitis treated with camoteskimab saw significant reductions in their mean EASI score at Week 16 compared to placebo.

In this analysis, the degree to which each dermatological condition impacts biological aging was highlighted using epigenetic clocks.

This letter explores off-label dosing adjustments for patients with psoriasis using the IL-17A inhibitors secukinumab and ixekizumab.

This review highlights several evidence-based approaches to promoting skin longevity and preventing signs of aging.

In this study, investigators assessed how the prescription patterns of biologics, non-biologic systemic agents, and phototherapy are altered after cardiovascular events.

A new position paper established an evidence-based definition for systemic corticosteroid (SCS) duration in individuals with atopic dermatitis.